Contact
searchSearch
HMP Global
Login

EGFR News

News
Osimertinib Plus Selumetinib Shows Limited Activity Following First-Line Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer
06/26/2026
Emily Estrada
Results from a phase 2 module of the ORCHARD study demonstrated that osimertinib plus selumetinib showed limited efficacy in patients with EGFR-mutated advanced non-small cell lung cancer harboring acquired BRAF alterations following disease...
Results from a phase 2 module of the ORCHARD study demonstrated that osimertinib plus selumetinib showed limited efficacy in patients with EGFR-mutated advanced non-small cell lung cancer harboring acquired BRAF alterations following disease...
Results from a phase 2 module of...
06/26/2026
Oncology
News
Asandeutertinib Demonstrates Superior Intracranial Efficacy in EGFR-Mutated NSCLC
05/31/2026
Emily Estrada
Results from the ESAONA asandeutertinib significantly improved intracranial response rates and intracranial progression-free survival in patients with EGFR-mutated NSCLC and brain metastases.
Results from the ESAONA asandeutertinib significantly improved intracranial response rates and intracranial progression-free survival in patients with EGFR-mutated NSCLC and brain metastases.
Results from the ESAONA...
05/31/2026
Oncology
News
Erlotinib Plus Ramucirumab Followed by Osimertinib Fails to Extend Time to Failure in EGFR-Mutated NSCLC
05/30/2026
Emily Estrada
Results from the phase 3 REVOL858R trial demonstrated that erlotinib plus ramucirumab followed by osimertinib did not improve outcomes in patients with EGFR-mutated advanced NSCLC.
Results from the phase 3 REVOL858R trial demonstrated that erlotinib plus ramucirumab followed by osimertinib did not improve outcomes in patients with EGFR-mutated advanced NSCLC.
Results from the phase 3...
05/30/2026
Oncology
News
Osimertinib Plus Chemotherapy Extends PFS in Molecularly High-Risk EGFR-Mutated NSCLC
05/30/2026
Emily Estrada
Results from the phase 2 FLAME study demonstrate that osimertinib plus chemotherapy significantly improves PFS in patients with EGFR-mutated advanced non-small cell lung cancer who remain ctDNA-positive after 3 weeks of first-line osimertinib.
Results from the phase 2 FLAME study demonstrate that osimertinib plus chemotherapy significantly improves PFS in patients with EGFR-mutated advanced non-small cell lung cancer who remain ctDNA-positive after 3 weeks of first-line osimertinib.
Results from the phase 2 FLAME...
05/30/2026
Oncology
News
Sunvozertinib Significantly Improves PFS in EGFR-Mutated Non-Small Cell Lung Cancer
05/29/2026
Stephanie Holland
Results from the phase 3 WU-KONG28 trial demonstrated that sunvozertinib significantly improved PFS in previously untreated patients with advanced EGFR-mutated non-small cell lung cancer.
Results from the phase 3 WU-KONG28 trial demonstrated that sunvozertinib significantly improved PFS in previously untreated patients with advanced EGFR-mutated non-small cell lung cancer.
Results from the phase 3...
05/29/2026
Oncology
News
Amivantamab Plus Lazertinib Improves First- and Second-Line Outcomes in EGFR-Mutated NSCLC
04/23/2026
Stephanie Holland
Post hoc analysis results from the MARIPOSA trial demonstrate that first-line amivantamab plus lazertinib improves second-line outcomes compared with osimertinib in EGFR-mutated non-small cell lung cancer.
Post hoc analysis results from the MARIPOSA trial demonstrate that first-line amivantamab plus lazertinib improves second-line outcomes compared with osimertinib in EGFR-mutated non-small cell lung cancer.
Post hoc analysis results from...
04/23/2026
Oncology
News
Sacituzumab Tirumotecan Improves Survival in EGFR-Mutated Non-Small Cell Lung Cancer
03/26/2026
Stephanie Holland
Updated results from the phase 3 OptiTROP-Lung03 trial demonstrate that sacituzumab tirumotecan significantly improves survival outcomes compared with docetaxel in previously treated patients with EGFR-mutated non-small cell lung cancer.
Updated results from the phase 3 OptiTROP-Lung03 trial demonstrate that sacituzumab tirumotecan significantly improves survival outcomes compared with docetaxel in previously treated patients with EGFR-mutated non-small cell lung cancer.
Updated results from the phase 3...
03/26/2026
Oncology
News
Osimertinib Plus Local Consolidative Therapy Improves PFS in EGFR-Mutated Non-Small Cell Lung Cancer
03/26/2026
Stephanie Holland
Results from the phase 2 NorthStar trial demonstrate that adding local consolidative therapy to osimertinib significantly improves outcomes in EGFR-mutated non-small cell lung cancer.
Results from the phase 2 NorthStar trial demonstrate that adding local consolidative therapy to osimertinib significantly improves outcomes in EGFR-mutated non-small cell lung cancer.
Results from the phase 2...
03/26/2026
Oncology
FDA Approval
FDA Approves Simplified Monthly Dosing Schedule for Subcutaneous Amivantamab Plus Hyaluronidase
02/18/2026
Stephanie Holland
The FDA approved a once-monthly dosing schedule for subcutaneous amivantamab plus hyaluronidase in combination with lazertinib for first-line treatment of EGFR-mutated advanced non–small cell lung cancer, based on findings from the phase 2...
The FDA approved a once-monthly dosing schedule for subcutaneous amivantamab plus hyaluronidase in combination with lazertinib for first-line treatment of EGFR-mutated advanced non–small cell lung cancer, based on findings from the phase 2...
The FDA approved a once-monthly...
02/18/2026
Oncology
News
Adjuvant Aumolertinib Improves Disease-Free Survival in Resected EGFR-Mutated Non–Small Cell Lung Cancer
01/21/2026
Stephanie Holland
Results from the phase 3 ARTS trial demonstrated that adjuvant aumolertinib significantly improved disease-free survival compared with placebo in patients with completely resected EGFR-mutated non-small cell lung cancer, supporting its use as...
Results from the phase 3 ARTS trial demonstrated that adjuvant aumolertinib significantly improved disease-free survival compared with placebo in patients with completely resected EGFR-mutated non-small cell lung cancer, supporting its use as...
Results from the phase 3 ARTS...
01/21/2026
Oncology

Recent News

FDA Approval
FDA Approves Gedatolisib Plus Fulvestrant for HR-Positive, HER2-Negative Metastatic Breast Cancer
07/14/2026
Stephanie Holland
The FDA approved gedatolisib in combination with fulvestrant, with or without palbociclib, for adults with PIK3CA wild-type HR-positive, HER2-negative locally advanced or metastatic breast cancer after endocrine therapy progression based on...
The FDA approved gedatolisib in combination with fulvestrant, with or without palbociclib, for adults with PIK3CA wild-type HR-positive, HER2-negative locally advanced or metastatic breast cancer after endocrine therapy progression based on...
The FDA approved gedatolisib in...
07/14/2026
Oncology
FDA Approval
FDA Grants Full Approval to Selpercatinib for RET Fusion-Positive Solid Tumors
07/14/2026
Stephanie Holland
The FDA granted traditional approval to selpercatinib for adults and children aged 2 years and older with previously treated RET fusion-positive solid tumors based on durable responses observed across multiple tumor types in the LIBRETTO-001...
The FDA granted traditional approval to selpercatinib for adults and children aged 2 years and older with previously treated RET fusion-positive solid tumors based on durable responses observed across multiple tumor types in the LIBRETTO-001...
The FDA granted traditional...
07/14/2026
Oncology
News
De-escalated Paclitaxel Plus Trastuzumab and Pertuzumab Yields Excellent Long-Term Outcomes in HER2-Positive Breast Cancer
07/14/2026
Stephanie Holland
Results from a prespecified secondary analysis of the phase 2 DAPHNe trial demonstrated that abbreviated neoadjuvant paclitaxel plus trastuzumab and pertuzumab produced excellent 5-year outcomes in patients with stage II to III HER2-positive...
Results from a prespecified secondary analysis of the phase 2 DAPHNe trial demonstrated that abbreviated neoadjuvant paclitaxel plus trastuzumab and pertuzumab produced excellent 5-year outcomes in patients with stage II to III HER2-positive...
Results from a prespecified...
07/14/2026
Oncology
FDA Approval
FDA Approves Pegfilgrastim Biosimilar ENNUMO for the Prevention of Febrile Neutropenia and Treatment of Acute Radiation Syndrome
07/13/2026
Stephanie Holland
The FDA approved ENNUMO, a biosimilar to pegfilgrastim, for the same indications as the reference product, providing an additional granulocyte colony-stimulating factor option to reduce febrile neutropenia during myelosuppressive chemotherapy...
The FDA approved ENNUMO, a biosimilar to pegfilgrastim, for the same indications as the reference product, providing an additional granulocyte colony-stimulating factor option to reduce febrile neutropenia during myelosuppressive chemotherapy...
The FDA approved ENNUMO, a...
07/13/2026
Oncology
FDA Alerts
FDA Accepts New Drug Application for Mezigdomide Combination in Relapsed or Refractory Multiple Myeloma
07/13/2026
Stephanie Holland
The FDA accepted the new drug application for mezigdomide plus carfilzomib and dexamethasone for relapsed or refractory multiple myeloma based on phase 3 SUCCESSOR-2 results demonstrating a significant progression-free survival benefit...
The FDA accepted the new drug application for mezigdomide plus carfilzomib and dexamethasone for relapsed or refractory multiple myeloma based on phase 3 SUCCESSOR-2 results demonstrating a significant progression-free survival benefit...
The FDA accepted the new drug...
07/13/2026
Oncology
News
Trastuzumab Rezetecan Improves Progression-Free Survival in Previously Treated HER2-Positive Metastatic Breast Cancer
07/10/2026
Stephanie Holland
Interim results from the phase 3 HORIZON-Breast01 trial demonstrated that trastuzumab rezetecan significantly improved progression-free survival compared with pyrotinib plus capecitabine in patients with previously treated HER2-positive...
Interim results from the phase 3 HORIZON-Breast01 trial demonstrated that trastuzumab rezetecan significantly improved progression-free survival compared with pyrotinib plus capecitabine in patients with previously treated HER2-positive...
Interim results from the phase...
07/10/2026
Oncology
FDA Approval
FDA Approves Subcutaneous Isatuximab Across Multiple Indications for Patients With Multiple Myeloma
07/10/2026
Emily Estrada
The FDA has approved subcutaneous isatuximab for three treatment indications in multiple myeloma, including in combination with pomalidomide and dexamethasone, carfilzomib and dexamethasone, or bortezomib, lenalidomide, and dexamethasone.
The FDA has approved subcutaneous isatuximab for three treatment indications in multiple myeloma, including in combination with pomalidomide and dexamethasone, carfilzomib and dexamethasone, or bortezomib, lenalidomide, and dexamethasone.
The FDA has approved...
07/10/2026
Oncology
News
Performance Status Predicts Real-World Outcomes With Tarlatamab in Extensive-Stage Small Cell Lung Cancer
07/09/2026
Stephanie Holland
A multicenter real-world study identified ECOG performance status as a key determinant of outcomes with tarlatamab in extensive-stage small cell lung cancer, with patients who had preserved functional status achieving survival comparable to...
A multicenter real-world study identified ECOG performance status as a key determinant of outcomes with tarlatamab in extensive-stage small cell lung cancer, with patients who had preserved functional status achieving survival comparable to...
A multicenter real-world study...
07/09/2026
Oncology
News
Adjuvant Ensartinib Demonstrates Significant Disease-Free Survival Benefit in ALK-Positive Non-Small Cell Lung Cancer
07/09/2026
Stephanie Holland
Results from the phase 3 ELEVATE trial demonstrated that adjuvant ensartinib significantly improved disease-free survival compared with placebo in patients with completely resected ALK-positive non-small cell lung cancer, supporting its use...
Results from the phase 3 ELEVATE trial demonstrated that adjuvant ensartinib significantly improved disease-free survival compared with placebo in patients with completely resected ALK-positive non-small cell lung cancer, supporting its use...
Results from the phase 3 ELEVATE...
07/09/2026
Oncology
FDA Alerts
FDA Accepts New Drug Application for Varegacestat in Adult Patients With Progressing Desmoid Tumors
07/09/2026
Emily Estrada
The FDA accepted the new drug application for varegacestat for adults with progressing desmoid tumors following positive results from the phase 3 RINGSIDE trial, supporting the investigational oral gamma secretase inhibitor as a potential new...
The FDA accepted the new drug application for varegacestat for adults with progressing desmoid tumors following positive results from the phase 3 RINGSIDE trial, supporting the investigational oral gamma secretase inhibitor as a potential new...
The FDA accepted the new drug...
07/09/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use